Compare Abbott Laboratories (ABT) vs CDW Corp. (CDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs CDW Corp. — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while CDW Corp. trades at $137.17 (market cap $17.79B). The key difference: Abbott Laboratories is far larger — about 9.4× CDW Corp.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | CDW | |
|---|---|---|
Market Cap | $166.94B | $17.79B |
Sector | Health | Technology |
52-Week High | $136.62 | $182.18 |
52-Week Low | $82.57 | $99.30 |
Enterprise Value | $193.69B | $23.00B |
Dividend Yield | 2.63% | 1.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CDW trades at $139.23, up 4.39% today, near its consensus price target of $142.17. The stock shows a bullish technical trend with strong moving averages, while fundamentals reflect steady revenue of $22.42B in 2025 and robust profitability with a 44.16% ROE. Recent news highlights AI infrastructure demand fueling growth, and the company increased its share repurchase program by $1 billion in May 2026.
Outlook is positive with analyst consensus strongly bullish (70.59% buy ratings), though risks include margin pressure and competitive threats. The stock offers value with a P/E of 16.34 and growth potential from AI adoption, but investors should monitor execution on earnings targets and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
